Abstract:Background: This study aims to evaluate the efficacy and therapeutic mechanism of bufalin on lung adenocarcinoma (LUAD) through a comprehensive strategy integrating network pharmacology, metabolomics and molecular biology verification. Methods: The putative targets of bufalin were discerned from PharmMapper and Swiss Target Prediction database. LUAD-related targets were obtained by target filtering of GeneCard database and data mining of GEO database. PPI network was constructed to screen the core targets, and their clinical significance was assessed through several public databases. GO and KEGG pathway analyses were performed to identify possible enrichment of genes with specific biological themes. Molecular docking and molecular dynamics (MD) simulation were employed to determine the correlation and binding pattern between bufalin and core targets. The potential mechanisms of bufalin acting on LUAD, as predicted by network pharmacology analyses, were experimentally validated using in-vitro and in-vivo models. Finally, the effects of bufalin intervention on metabolite profile and metabolic pathway in LUAD nude mice were investigated by non-targeted metabolomics. Results: 209 bufalin targets and 1082 LUAD-associated targets were harvested, of which 51 intersection targets were identified. 10 core targets including Akt1, STAT3, EGFR, CASP3 and SRC were picked out through network topology analysis, and they had a potent binding activity with bufalin as indicated by molecular docking and MD simulation. Hub module of PPI network was closely related to cell proliferation and apoptosis. GO and KEGG enrichment analyses suggested that bufalin exerted therapeutic effects on LUAD possibly by inhibiting proliferation and promoting apoptosis via PI3K/Akt, FoxO1 and MAPK/ERK pathways, which were confirmed by a series of in-vitro studies as well as HE, TUNEL and Ki-67 staining of tumor tissues. Further metabolomics analysis revealed that bufalin mainly regulated ABC transporter and remodeled AA metabolism, thereby contributing to the treatment of LUAD. Conclusion: From molecular and metabolic perspective, the present study not only provided a unique insight into the possible mechanisms of bufalin against LUAD after successfully filtering out associated key target genes, differential endogenous metabolites, and signaling pathways, but also proposed a novel promising therapeutic strategy for LUAD.

Bufalin Suppresses Hepatocellular Carcinoma Invasion and Metastasis by Targeting HIF-1α Via the PI3K/AKT/mTOR Pathway.

Bufalin Inhibits Htert Expression and Colorectal Cancer Cell Growth by Targeting CPSF4

Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice

Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma Via Modulating the ATP1A1/CA2 Axis

Bufalin Enhances Anti-Angiogenic Effect of Sorafenib Via AKT/VEGF Signaling.

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma

Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signaling

Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells

Bufalin targeting BFAR inhibits the occurrence and metastasis of gastric cancer through PI3K/AKT/mTOR signal pathway

Molecular and metabolic mechanisms of bufalin against lung adenocarcinoma: New and comprehensive evidences from network pharmacology, metabolomics and molecular biology experiment

Bufalin Inhibits Tgf-Beta-Induced Epithelial-To-Mesenchymal Transition And Migration In Human Lung Cancer A549 Cells By Downregulating Tgf-Beta Receptors

Na+/K+-Atpase Alpha 3 Mediates Sensitivity Of Hepatocellular Carcinoma Cells To Bufalin

Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells

Bufalin Enhances the Anti-Proliferative Effect of Sorafenib on Human Hepatocellular Carcinoma Cells Through Downregulation of ERK

Global Metabolomic and Lipidomic Analysis Reveal the Synergistic Effect of Bufalin in Combination with Cinobufagin Against HepG2 Cells.

The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma

Synergistic Anti-Hepatoma Effect of Bufalin Combined with Sorafenib Via Mediating the Tumor Vascular Microenvironment by Targeting Mtor/vegf Signaling

High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells.

[A 10-year follow-up of cases with anorexia first hospitalized in the Canton of Zürich].

Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species‑mediated apoptosis by targeting the electron transport chain

Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways